Home/Cases/Setterwalls has advised Alligator Bioscience in connection with rights issue of ... case / 03 Dec 2021Share / Setterwalls has advised Alligator Bioscience in connection with rights issue of approximately SEK 257 million Setterwalls has advised Alligator Bioscience AB (“Alligator”), listed on Nasdaq Stockholm, in connection with a rights issue of shares of approximately SEK 257 million. The rights issue was subscribed to approximately 121 per cent. Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s shares are listed on Nasdaq Stockholm, and the company is headquartered in Lund, Sweden. Contact: Ola Grahn, Ludwig Isell Lind af Hageby, Joakim Winnerljung, Erik Olshov Practice areas: Equity Capital Markets, Life Sciences Back Next article